The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III
Latest Information Update: 08 Aug 2016
Price : $35 *
At a glance
- Drugs DLBS 1449 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Dexa Medica
- 03 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Feb 2016 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
- 11 Feb 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov record.